Genmab A S Is A Danish Biotechnology Company Founded In February 1999 And Headquartered In Copenhagenthe Company Specializes In Developing Antibody Based Therapeutics Aimed At Treating Cancer And Other Serious Diseasesgenmab S Mission Is To Enhance Patient Lives Through Innovative Antibody Solutions The Company Has Developed Several Marketed Productsincluding Ofatumumabkesimptafor Relapsing Multiple Sclerosisdaratumumabdarzalexfor Al Amyloidosis And Multiple Myelomaand Teprotumumabtepezzafor Thyroid Eye Diseasegenmab Employs Proprietary Technologies Such As Hexabodyduobodyduohexabodyand Hexelect In Its Product Developmentit Collaborates With Various Pharmaceutical And Biotechnology Companies To Co Develop And Commercialize Its Therapiesensuring A Global Reach For Its Products As Of 2023Genmab Reported A Revenue Of Dkk 16 474 Billionreflecting Its Strong Performance In The Biotech Sectorthe Company Is Led By Ceo Professor Jan Van De Winkel And Has A Diverse Ownership Structure That Includes Institutional Investors And Public Shareholders
